A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco

Pfizer

Status: Withdrawn

Conditions: COVID-19 Drug Treatment

Treatments: Drug: Nirmatrelvir/Ritonavir

Study type: Observational

Funder types: Industry

Identifiers

NCT05997485

C4671060

Details and patient eligibility

About

The purpose of this study is to collect information on the:

• general information of a group of people such as their age, sex, and other facts.
• clinical information of the patients such as any other illness before having COVID 19.

In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir treatment.

This study will be conducted in Morocco. The study will capture information of the adult COVID-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavir treatment. The inpatients will be admitted in the hospital for other reasons than COVID-19.

This study will have about 150 patients. The study will involve collection of patient information from medical records. The information collected can be either from papers or from computers.

The study will include patient information of those who:

• are confirmed to have COVID-19 infection during the study period from 01 June 2022 to 30 June 2023.
• are 18 years of age or older.
• are prescribed Nirmatrelvir and ritonavir. This study will help to inform decision-making on use of Paxlovid at the national level.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed COVID-19 infection during the study period from 01 June 2022 to 30 June 2023
• Nirmatrelvir, ritonavir written prescription

Exclusion criteria

• There are no exclusion criteria for this study.

Trial design

0 participants in 1 patient group

Participants receiving Paxlovid Treatment

Description:

Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.

Treatment:

Drug: Nirmatrelvir/Ritonavir